FDA Approval Summary: Midostaurin for the Treatment of Advanced Systemic Mastocytosis

In April 2017, the U.S. Food and Drug Administration granted regular approval to midostaurin for the treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM‐AHN), or mast cell leukemia (MCL). Approval was based on resu...

Descripción completa

Detalles Bibliográficos
Autores principales: Kasamon, Yvette L., Ko, Chia‐Wen, Subramaniam, Sriram, Ma, Lian, Yang, Yuching, Nie, Lei, Shord, Stacy, Przepiorka, Donna, Farrell, Ann T., McKee, Amy E., Pazdur, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2018
Materias:
Regulatory Issues: FDA
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6292539/
https://www.ncbi.nlm.nih.gov/pubmed/30115735
http://dx.doi.org/10.1634/theoncologist.2018-0222

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6292539/
https://www.ncbi.nlm.nih.gov/pubmed/30115735
http://dx.doi.org/10.1634/theoncologist.2018-0222

Ejemplares similares